1. Inhibitory Antibodies
  2. Narnatumab

Narnatumab  (Synonyms: IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab))

Cat. No.: HY-P99375

Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer.

For research use only. We do not sell to patients.

CAS No. : 1188275-92-4

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer[1].

Isotype

Human IgG1 kappa

Recommend Isotype Controls
Species

Human

IC50 & Target

RON(MSPR)[1]

In Vitro

Narnatumab (100 nM; 24 h) inhibits MSP-induced migration of human lung and breast cancer cell lines[1].
Narnatumab inhibits the MSP-induced mitogenic response of a pancreatic cancer cell line[1].
Narnatumab (0.01-100 nM; pretreatment for 1 h) blocks ligand-induced receptor phosphorylation and downstream signaling molecules phosphorylation in RON-expressing tumor cells and in a RON-transfected cell line[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Narnatumab (2-60 mg/kg; i.p. every 3 days) shows antitumor activity in non-small cell lung cancer (NSCLC) and bladder cancer models in athymic mice[1].
Narnatumab exhibits terminal half-life (t1/2=5.2 d) and achieves antitumor effects at a steady-state plasma trough level of approximately 140 μg/mL in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells[1]
Dosage: 2, 20, 60 mg/kg
Administration: I.p. every 3 days for 36 and 18 days
Result: Inhibited tumor growth in a dose-dependent manner.
CAS No.
SMILES

[Narnatumab]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Narnatumab
Cat. No.:
HY-P99375
Quantity:
MCE Japan Authorized Agent: